Skip to main content

Advertisement

Fig. 6 | Molecular Cancer

Fig. 6

From: Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer

Fig. 6

Schematic figure for present study. Cancer-associated fibroblast (CAF)-induced interleukin-6 (IL-6) activates the Jak1-STAT3 pathway in gastric cancer cells via paracrine signaling, which allows tumor cells to increasingly oppose apoptosis and increase their survival and resistance to chemotherapy. Tocilizumab, a humanized monoclonal anti-IL-6R antibody that is an FDA-approved drug, inhibits the CAF-induced activation of the Jak1-STAT3 signaling pathway in gastric cancer cells and consequently increases the efficacy of chemotherapeutic drugs

Back to article page